Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC meetings

This article was originally published in The Tan Sheet

Executive Summary

Nonprescription drugs advisory panel will meet jointly with the Dermatologic & Ophthalmic committee to "discuss what should be the necessary and sufficient safety database in order to evaluate the [Rx-to-OTC] switch of topical corticosteroids, especially the database to evaluate the potential for hypothalamic, pituitary, adrenal (HPA) and growth suppression and other systemic and local adverse reactions." The committee will convene at the Washington D.C. Hilton on March 24 from 8 am-5:30 pm, with the hour between 1 pm-2 pm reserved for public comment. NDAC will hold a separate meeting on March 23 to evaluate "microbiologic surrogate endpoints used to demonstrate the effectiveness of antiseptic products used in health care settings"...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097851

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel